South San Francisco, CA — February 5th, 2018 —
In the midst of one of the most severe flu seasons in the US in nearly a decade, Genentech understands patients may be having difficulty accessing generic oseltamivir treatment. At this time, Genentech continues to have supply of all configurations of branded Tamiflu and has continued to work to provide this medicine to patients.
Over the last month, CDC has stated concerns in media briefings and on the CDC website regarding spot shortages of generic oseltamivir impacting access to the drug in the market place.
In order to improve patient access to branded Tamiflu in response to the public health concerns Genentech will:
We believe these efforts will positively impact patient access to Tamiflu during the remainder of the 2017-2018 flu season.
Tamiflu is a prescription medicine used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days. Tamiflu can also reduce the chance of getting the flu in people 1 year and older.
Tamiflu does not prevent bacterial infections that may happen with the flu.
Tamiflu is not a substitute for an annual flu vaccination.
Patients must not take Tamiflu if they are allergic to oseltamivir phosphate or any of the ingredients in Tamiflu.
Important Safety Information
Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch.
Patients and caregivers may also report side effects to Genentech at (888) 835-2555.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.